GenixPharmaceucticals Corporation (GENX) - Total Assets
Based on the latest financial reports, GenixPharmaceucticals Corporation (GENX) holds total assets worth CA$33.36K CAD (≈ $24.13K USD) as of April 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
GenixPharmaceucticals Corporation - Total Assets Trend (2015–2025)
This chart illustrates how GenixPharmaceucticals Corporation's total assets have evolved over time, based on quarterly financial data. Also see GENX market cap for the company's overall valuation and market capitalisation.
GenixPharmaceucticals Corporation - Asset Composition Analysis
Current Asset Composition (October 2025)
GenixPharmaceucticals Corporation's total assets of CA$33.36K consist of 100.0% current assets and 0.0% non-current assets. Review GenixPharmaceucticals Corporation balance sheet liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 85.5% |
| Accounts Receivable | CA$1.74K | 3.4% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$5.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2015–2025)
This chart illustrates how GenixPharmaceucticals Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See GENX share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: GenixPharmaceucticals Corporation's current assets represent 100.0% of total assets in 2025, an increase from 68.6% in 2015.
- Cash Position: Cash and equivalents constituted 85.5% of total assets in 2025, up from 43.7% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2015.
- Asset Diversification: The largest asset category is accounts receivable at 3.4% of total assets.
GenixPharmaceucticals Corporation Competitors by Total Assets
Key competitors of GenixPharmaceucticals Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
|
Germany | €1.60 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Beijing Tongrentang Co Ltd
SHG:600085
|
China | CN¥31.82 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Neuland Laboratories Limited
NSE:NEULANDLAB
|
India | Rs29.30 Billion |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
|
China | CN¥17.01 Billion |
GenixPharmaceucticals Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.02 | 0.03 | 0.51 |
| Quick Ratio | 0.02 | 0.03 | 0.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-1.55 Million | CA$-1.35 Million | CA$-282.29K |
GenixPharmaceucticals Corporation - Advanced Valuation Insights
This section examines the relationship between GenixPharmaceucticals Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.04 |
| Latest Market Cap to Assets Ratio | 17.37 |
| Asset Growth Rate (YoY) | 11.9% |
| Total Assets | CA$50.98K |
| Market Capitalization | $885.77K USD |
Valuation Analysis
Premium Asset Valuation: The market values GenixPharmaceucticals Corporation's assets at a significant premium (17.37x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: GenixPharmaceucticals Corporation's assets grew by 11.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for GenixPharmaceucticals Corporation (2015–2025)
The table below shows the annual total assets of GenixPharmaceucticals Corporation from 2015 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-10-31 | CA$50.98K ≈ $36.88K |
+11.93% |
| 2024-10-31 | CA$45.55K ≈ $32.95K |
-79.62% |
| 2023-10-31 | CA$223.46K ≈ $161.65K |
-94.75% |
| 2022-10-31 | CA$4.25 Million ≈ $3.08 Million |
-10.84% |
| 2021-10-31 | CA$4.77 Million ≈ $3.45 Million |
-10.81% |
| 2020-10-31 | CA$5.35 Million ≈ $3.87 Million |
+13176.71% |
| 2019-10-31 | CA$40.27K ≈ $29.13K |
-82.62% |
| 2018-10-31 | CA$231.72K ≈ $167.62K |
-41.15% |
| 2017-10-31 | CA$393.77K ≈ $284.85K |
-12.97% |
| 2016-10-31 | CA$452.47K ≈ $327.31K |
-26.75% |
| 2015-10-31 | CA$617.66K ≈ $446.81K |
-- |
About GenixPharmaceucticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral,… Read more